SCHEMBL32665461

SCHEMBL32665461

O=C1C=CC(=O)N1C1CC2(CCN(Cc3ccc(O)cc3)CC2)C1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 3/20 0.39
CHRM2 P08172 1/20 0.39
CHRM3 P20309 1/20 0.39
LMNA P02545 1/20 0.38
KMT2A Q03164 5/20 0.38
MEN1 O00255 4/20 0.38
CYP2C9 P11712 3/20 0.38
TSHR P16473 2/20 0.38
SIGMAR1 Q99720 1/20 0.38
CYP1A2 P05177 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
HIF1A Q16665 2/20 0.38
CYP3A4 P08684 2/20 0.38
ACHE P22303 1/20 0.38
BACE1 P56817 1/20 0.38
ALDH1A1 P00352 2/20 0.37
DRD4 P21917 1/20 0.37
CYP2C19 P33261 1/20 0.37
USP2 O75604 2/20 0.36
P4HB P07237 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32665228 0.85 CHRM2 (0.46) CYP2D6CHRM2CHRM3LMNAKMT2A
SCHEMBL32665137 0.80 HRH3 (0.36) CYP2D6LMNAKMT2AMEN1CYP2C9
SCHEMBL32665615 0.80 TDP1 (0.41) LMNAKMT2AMEN1CYP2C9CYP1A2
SCHEMBL32665369 0.77 ACHE (0.43) CYP2D6CHRM2CHRM3LMNAKMT2A
SCHEMBL32665089 0.73 DOCK5 (0.35) LMNASIGMAR1ALDH1A1MAPK1
SCHEMBL32665432 0.73 NPSR1 (0.36) CHRM2CHRM3KMT2AMEN1SIGMAR1
SCHEMBL32665508 0.72 CCR8 (0.39) CYP2D6CHRM2CHRM3SIGMAR1CYP3A4
SCHEMBL32665203 0.70 HTR7 (0.42) CYP2D6KMT2AMEN1CYP1A2DRD4
SCHEMBL12642507 0.70 CYP2D6 (0.76) CYP2D6CHRM2CHRM3KMT2AMEN1
SCHEMBL5428090 0.69 DRD4 (0.63) LMNASIGMAR1ACHEBACE1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260021192-A1 PROTEINS HAVING A COVALENT WARHEAD TOPAZ THERAPEUTICS INC (US) 2026-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260021192-A1 PROTEINS HAVING A COVALENT WARHEAD RIOX2, ORC3, DCLRE1A CYP2D6 4329/4885CHRM2 4716/4885CHRM3 4644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.